文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

ARDS ROSE 试验中通气比早期测值的预后价值

The prognostic value of early measures of the ventilatory ratio in the ARDS ROSE trial.
PubMed 文献 · Crit Care · 2022-09-29
一句话结论ARDS 患者基线及第1天通气比升高与28天死亡率升高相关,通气比轨迹可能适用于预后判断与预测富集,且无需因神经肌肉阻滞校正。

本文为 PETAL-ROSE 试验的事后分析,该试验将中重度 ARDS 患者随机分配至神经肌肉阻滞(NMB)组或对照组。恶化型通气比轨迹患者的生存率显著低于改善型轨迹患者(n=602,p<0.05)。第1天通气比>2(中位数)者90天生存率显著低于≤2者(HR 1.36,95% CI 1.10-1.69),第1天通气比与28天死亡率显著相关(OR=1.40,95% CI 1.15-1.72)。通气比上升轨迹与死亡率显著相关且独立于NMB、基线PaO2/FiO2及总体疾病严重度标志(28天校正OR 1.81,95% CI 1.28-2.84;90天OR 2.07,95% CI 1.41-3.10)。APACHE-III与基线通气比存在显著交互,APACHE-III较低者中通气比与死亡率的关系更强;APACHE-III和NMB均非通气比轨迹与死亡率关系的效应修饰因子。

要点

  • ARDS患者第1天通气比>2(中位数)者90天生存率显著低于≤2者(HR 1.36,95% CI 1.10-1.69)。
  • 第1天通气比与28天死亡率显著相关(OR=1.40,95% CI 1.15-1.72)。
  • 通气比上升轨迹与28天死亡率独立相关(校正OR 1.81,95% CI 1.28-2.84),与90天死亡率亦独立相关(OR 2.07,95% CI 1.41-3.10)。
  • APACHE-III与基线通气比对28天死亡率存在显著交互,APACHE-III较低者中通气比与死亡率关系更强。
  • NMB与通气比无交互,通气比在NMB组与对照组间无差异,提示使用通气比无需因NMB校正。

适用人群与场景

  • PETAL-ROSE试验纳入的中重度ARDS患者,随机分配至神经肌肉阻滞(NMB)组或对照组。

诊断标准与关键阈值

  • 通气比(VR)计算公式:[分钟通气量×PaCO2]/[预测体重×100×37.5]。
  • 以第1天通气比中位数2为界值分组:VR>2与VR≤2。

研究设计与关键结果

  • 研究类型:PETAL-ROSE随机试验的事后分析,样本量n=602。
  • 恶化型通气比轨迹患者生存率显著低于改善型轨迹患者(p<0.05)。
  • 第1天VR>2(中位数)者90天生存率显著低于VR≤2者(HR 1.36,95% CI 1.10-1.69)。
  • 第1天VR与28天死亡率显著相关(OR=1.40,95% CI 1.15-1.72)。
  • NMB与VR对28天死亡率无交互作用。
  • APACHE-III与基线VR对28天死亡率存在显著交互,APACHE-III较低者中VR与死亡率关系更强。
  • 通气比上升轨迹与死亡率显著相关,独立于NMB、基线PaO2/FiO2及总体疾病严重度标志:28天校正OR 1.81(95% CI 1.28-2.84),90天OR 2.07(95% CI 1.41-3.10)。
  • APACHE-III和NMB均非通气比轨迹与死亡率关系的效应修饰因子。

证据类型、等级与局限

  • 证据类型:随机对照试验(PETAL-ROSE)的事后分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,由于APACHE-III不是通气比轨迹与死亡率关系的效应修饰因子,通气比轨迹可能最适合用于预后判断和预测富集。
  • 通气比在NMB组与对照组间无差异,提示使用通气比时无需因NMB进行校正。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The ventilatory ratio (VR, [minute ventilation × PaCO2]/[predicted body weight × 100 × 37.5]) is associated with mortality in ARDS. The aims of this study were to test whether baseline disease severity or neuromuscular blockade (NMB) modified the relationship between VR and mortality.

METHODS: This was a post hoc analysis of the PETAL-ROSE trial, which randomized moderate-to-severe ARDS patients to NMB or control. Survival among patients with different VR trajectories or VR cutoff above and below the median was assessed by Kaplan-Meier analysis. The relationships between single-day or 48-h VR trajectories with 28- or 90-day mortality were tested by logistic regression. Randomization allocation to NMB and markers of disease severity were tested as confounders by multivariable regression and interaction term analyses.

RESULTS: Patients with worsening VR trajectories had significantly lower survival compared to those with improving VR (n = 602, p < 0.05). Patients with VR > 2 (median) at day 1 had a significantly lower 90-day survival compared to patients with VR ≤ 2 (HR 1.36, 95% CI 1.10-1.69). VR at day 1 was significantly associated with 28-day mortality (OR = 1.40, 95% CI 1.15-1.72). There was no interaction between NMB and VR for 28-day mortality. APACHE-III had a significant interaction with VR at baseline for the outcome of 28-day mortality, such that the relationship between VR and mortality was stronger among patients with lower APACHE-III. There was a significant association between rising VR trajectory and mortality that was independent of NMB, baseline PaO2/FiO2 ratio and generalized markers of disease severity (Adjusted OR 1.81, 95% CI 1.28-2.84 for 28-day and OR 2.07 95% CI 1.41-3.10 for 90-day mortality). APACHE-III and NMB were not effect modifiers in the relationship between VR trajectory and mortality.

CONCLUSIONS: Elevated baseline and day 1 VR were associated with higher 28-day mortality. The relationship between baseline VR and mortality was stronger among patients with lower APACHE-III. APACHE-III was not an effect modifier for the relationship between VR trajectory and mortality, so that the VR trajectory may be optimally suited for prognostication and predictive enrichment. VR was not different between patients randomized to NMB or control, indicating that VR can be utilized without correcting for NMB.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Monteiro ACC, Vangala S, Wick KD, et al. The prognostic value of early measures of the ventilatory ratio in the ARDS ROSE trial. Crit Care. 2022. PMID: 36175982. doi:10.1186/s13054-022-04179-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。